Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.

Abstract	Seventy-nine adult patients with acute nonlymphoblastic leukemia (ANLL) were treated on the L-6 protocol at Memorial Sloan-Kettering Cancer Center between May 1970 and January 1974. Forty-two patients achieved a complete remission (CR) and nine of these are still disease free, with a minimum of seven years of follow-up. An extensive statistical analysis has been carried out on a large number of pretreatment and treatment characteristics to identify factors related to CR and remission duration. Multivariate regression techniques yielded as favorable characteristics associated with CR, in order of importance: young age at diagnosis, the presence of Auer rods at diagnosis, and treatment with Pseudomonas vaccine. A regression model for remission duration identified as favorable prognostic factors for long-term remission: at most two courses of induction therapy, an intermediate age range, and a low platelet count at diagnosis.
Authors	S Passe, V Miké, R Mertelsmann, T S Gee, B D Clarkson
Journal	Cancer (Cancer) Vol. 50 Issue 8 Pg. 1462-71 (Oct 15 1982) ISSN: 0008-543X [Print] United States
PMID	7116285 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References	Antineoplastic Agents Bacterial Vaccines Cytarabine Vincristine Cyclophosphamide Thioguanine Carmustine Hydroxyurea Methotrexate Daunorubicin
Topics	Acute Disease Adolescent Adult Age Factors Aged Antineoplastic Agents (administration & dosage) Antineoplastic Combined Chemotherapy Protocols Bacterial Vaccines (therapeutic use) Carmustine (administration & dosage) Cyclophosphamide (administration & dosage) Cytarabine (administration & dosage) Daunorubicin (administration & dosage) Drug Therapy, Combination Female Follow-Up Studies Humans Hydroxyurea (administration & dosage) Leukemia (drug therapy, pathology) Male Methotrexate (administration & dosage) Middle Aged Platelet Count Prognosis Pseudomonas (immunology) Statistics as Topic Thioguanine (administration & dosage) Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!